Target intelligence / Profile preview

T cell receptor beta joining 2-6 (TRBJ2-6)

Target: TRBJ2-6
Molecular classification: Joining gene segment (J), Immunoglobulin superfamily (part of TCR complex), Other (does not encode functional receptor protein itself, but rather contributes to receptor diversity)

Overview

TRBJ2-6 (T cell receptor beta joining 2-6) is one of the joining (J) gene segments of the T cell receptor beta (TCRβ) locus. These segments play a central role in the assembly of the TCR beta chain via somatic recombination, forming the highly diverse complementarity-determining region 3 (CDR3) that enables T cells to recognize a vast array of peptide antigens presented by major histocompatibility complex (MHC) molecules[7][2][5]. In the human TCR beta locus, multiple joining gene segments (including TRBJ2-6) are available for recombination, contributing to the immense structural diversity of T cell receptors and enabling effective adaptive immune defense. TRBJ2-6 itself is not a receptor or protein but encodes part of the final TCRβ protein sequence after recombination. It is essential for generating antigen specificity in T cells, but is not directly targeted by therapeutic agents nor commonly used as a clinical biomarker[7][5][3].

Other names: TRBJ2-6TRBJ26TCRBJ2S6

Biological functions

Generates diversity in antigen recognition by contributing to the variable region of TCR beta chain[7][5]Participates in adaptive immune response[2][7]

Disease associations

Other (not directly implicated as a disease driver, but changes in TCR repertoire can be associated with immune-related diseases, cancer, infection, and autoimmunity[5][7])

Beyond the preview

Go deeper on T cell receptor beta joining 2-6 (TRBJ2-6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 2-6 (TRBJ2-6).

Explore the full profile